Content area

Abstract

ABSTRACT

Background

Myotonic Dystrophy type 1 (DM1) is an autosomal dominant disease with anticipation due to increased number of CTG repeats in the DMPK gene.

Methods

This retrospective, cohort study in Iceland assessed prevalence of DM1, molecular pathology, and patient ascertainment. Data was collected from all major hospitals in Iceland, Medical Director of Health, and independent clinics. Cohort criteria were diagnosis of DM1 on January 1, 2021, or time of death. Population‐based Icelandic Genealogy Database of the Genetical Committee at the University of Iceland was used for genealogy.

Results

In Iceland, 221 individuals, including 19 obligate carriers, had been diagnosed with DM1 of which 144 were alive giving a point prevalence of 39 per 100,000 (four times the world average of 9.3). Genealogy analysis identified 45 first‐degree families. Age‐adjusted prevalence ranged between 11 and 66 per 100,000. Average potential years of life lost were 20.5 per person. Where information was available, 63% of ascertainment was based on family history in cascade testing.

Conclusion

The differences in age‐adjusted prevalence suggest that the overall point prevalence is an underestimation due to underdiagnosis in younger age groups and lethality in oldest age group. Our data supports use of cascade testing to improve DM1 ascertainment.

Details

1009240
Business indexing term
Title
Molecular Pathology of Myotonic Dystrophy Type 1 in Iceland
Author
Hallgrímsdóttir, E. G. 1 ; Svansson, H. 1 ; Stefánsdóttir, V. F. 2 ; Sveinsson, Ó. Á. 3 ; Ólafsdóttir, H. 2 ; Briem, E. 2   VIAFID ORCID Logo  ; Sveinbjörnsdóttir, S. 4 ; Jónsson, J. J. 5   VIAFID ORCID Logo 

 School of Medicine, European University Cyprus, Nicosia, Cyprus, Department of Medicine, Aarhus University, Aarhus, Denmark, Department of Genetics and Molecular Medicine, Landspítali‐National University Hospital of Iceland, Reykjavík, Iceland 
 Department of Genetics and Molecular Medicine, Landspítali‐National University Hospital of Iceland, Reykjavík, Iceland 
 Department of Neurology, Landspítali‐National University Hospital of Iceland, Reykjavík, Iceland, Faculty of Medicine, University of Iceland, Reykjavík, Iceland 
 MSE Trust, Basildon University Hospital, Queen Mary University of Medicine and Dentistry, University of London, London, UK 
 Department of Genetics and Molecular Medicine, Landspítali‐National University Hospital of Iceland, Reykjavík, Iceland, Faculty of Medicine, University of Iceland, Reykjavík, Iceland 
Publication title
Volume
12
Issue
10
Publication year
2024
Publication date
Oct 1, 2024
Section
ORIGINAL ARTICLE
Publisher
John Wiley & Sons, Inc.
Place of publication
Bognor Regis
Country of publication
United States
Publication subject
e-ISSN
23249269
Source type
Scholarly Journal
Language of publication
English
Document type
Journal Article
Publication history
 
 
Online publication date
2024-10-07
Milestone dates
2024-08-05 (manuscriptRevised); 2024-10-07 (publishedOnlineFinalForm); 2023-10-01 (manuscriptReceived); 2024-09-10 (manuscriptAccepted)
Publication history
 
 
   First posting date
07 Oct 2024
ProQuest document ID
3121184884
Document URL
https://www.proquest.com/scholarly-journals/molecular-pathology-myotonic-dystrophy-type-1/docview/3121184884/se-2?accountid=208611
Copyright
© 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Last updated
2024-11-06
Database
ProQuest One Academic